Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

both locally and in distant sites in the body.  This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated.  Normal cells are not affected by JX-594 resulting in safety and tolerability.

The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program.  This strain naturally targets cancer cells due to common genetic defects in cancer cells.  JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells.  To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein.  GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers.  Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells.  These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut off the blood supply to tumors, as well as stimulating the body's immune response to the cancer.  Jennerex, Inc. is headquartered in

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut ... launch this month to spend a year living and working ... satellite interviews from 5:30 to 7 a.m. EDT Monday, March ... as he completes the final weeks of his ... a video on NASA Television highlighting his mission training and ...
(Date:3/3/2015)... 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and Chief Executive Officer of Neurocrine Biosciences, will ... Miami.   The live presentation takes place ... The presentation will be webcast and may be accessed ... Listeners are encouraged to visit the website ...
(Date:3/3/2015)... Crown Bioscience, Inc., a leading global drug ... Life Science division specializing in in vivo and in ... first products released include in vivo grade human and ... released in vivo grade monoclonal antibodies against PD-L1 and ... science portfolio with additional antibody products as well as ...
Breaking Biology Technology:Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Crown Bioscience Launches Life Science Product Catalog 2
... at ... Nanopatterning Leader, AUSTIN, Texas, July 1 ... solutions, today,announced that Ben Eynon and Paul Hofemann have joined its ... of marketing and business development for semiconductors, and,vice president of marketing ...
... Trials ... of Drug Development, HAMILTON, N.J., July 1 ... today that it has,closed a $20 million financing by ... developed an innovative platform to centralize and,calibrate the assessment ...
... Inc. (Nasdaq: MGRM ) announced today that William ... update on the company,s business,at the Collins Stewart LLC ... 9:00 a.m. (Eastern Time) at the Mandarin Oriental Hotel ... broadcast or the subsequent archived,recording, log on to ...
Cached Biology Technology:Industry Veterans Join Molecular Imprints' Management Team 2Industry Veterans Join Molecular Imprints' Management Team 3MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 2MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 3MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 4Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference 2
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Our genes control many aspects of who we are ... certain diseases but how are the genes, and consequently ... have discovered a new group of molecules which control some ... the key to developing new therapies for treating neurodegenerative diseases. ...
... assistant professor in the Department of Chemistry and Biochemistry ... Faculty Early Career Development Award from the National Science ... modeling methods to study the biophysics of model cell ... award also will support the purchase of a computer ...
... JUPITER, FL, April 27, 2012 A scientist from ... been awarded $1.5 million from the National Institutes of ... new therapeutics targeting RNA., Matthew Disney, an associate professor ... four-year study. , RNA was once considered a passive ...
Cached Biology News:Doubling the information from the double helix 2Patel recognized with NSF Career Award for computer-modeling research on cell membranes 2Patel recognized with NSF Career Award for computer-modeling research on cell membranes 3
... Ambions 96 well Magnetic-Ring Stand is designed ... well U-bottom microplates. The stand has a ... well microtiter plate footprint. The use of ... fast and easy magnetic separation. With this ...
6B9...
Request Info...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: